Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868641 · ClinicalTrials.gov registry record · NA
The TAIL-PrEP Study
A NA study, sponsored by Columbia University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT06868641: Recruiting NA study, sponsored by Columbia University.
NCT06868641 is a NA study that is actively recruiting participants, run by Columbia University. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06868641, a NA study, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of the TAIL-PrEP study is to understand how to support the safe discontinuation of injectable long-acting cabotegravir (cab-LA) and lenacapavir (LEN) while maximizing the public health impact of biomedical HIV prevention interventions. In Aim 1, the study will pilot test and assess the acceptability and feasibility of the TAIL-PrEP intervention: for participants discontinuing cab-LA, this will consist of monthly cabotegravir drug level monitoring to provide personalized HIV prevention coaching, for participants considering discontinuing cab-LA or LEN, this will consist of a one-time personalized HIV prevention coaching session. In Aim 2, the study will refine the TAIL-PrEP intervention and implementation strategy based on findings from the pilot study.
Primary Outcome
Acceptability of the intervention will be assessed using the validated Acceptability of Intervention Measure (AIM). AIM is a 4-item scale where respondents rate each item using a 5-point ordinal scale that ranges from 1="completely disagree" to 5="completely agree". The AIM is scored by averaging responses across the 4 items. A higher average score indicates greater acceptability, which is a better outcome.
Interventions
- BEHAVIORAL TAIL-PrEP for patients discontinuing cab-LA
- BEHAVIORAL TAIL-PrEP for patients considering discontinuing cab-LA
- BEHAVIORAL TAIL-PrEP for patients considering discontinuing LEN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-03 |
| Phase | NA |
What NCT06868641 shows while recruiting
NCT06868641 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which TAIL-PrEP for patients discontinuing cab-LA is the first listed.
NCT06868641 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06868641 about?
NCT06868641 is a clinical study titled "The TAIL-PrEP Study". The goal of the TAIL-PrEP study is to understand how to support the safe discontinuation of injectable long-acting cabotegravir (cab-LA) and lenacapavir (LEN) while maximizing the public health impact of biomedical HIV prevention interventions. In Aim 1, the study will pilot test and assess the acce...
What is the current status of trial NCT06868641?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-06. Estimated completion is 2027-03.
What interventions are being tested in trial NCT06868641?
The interventions under investigation include: TAIL-PrEP for patients discontinuing cab-LA (BEHAVIORAL), TAIL-PrEP for patients considering discontinuing cab-LA (BEHAVIORAL), TAIL-PrEP for patients considering discontinuing LEN (BEHAVIORAL).
Who is sponsoring clinical trial NCT06868641?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06868641's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia